TY  - JOUR
T1  - Clinical profile, treatment, and outcomes of patients with mantle cell lymphoma treated in a tertiary care center in South India
A1  - Kadabur Lokesh
A1  - Sunny Garg
A1  - Lakshmaiah Kuntegowdanahalli
A1  - Govinda Kanakasetty
A1  - Premalata Srinivasamurthy
A1  - Suparna Rao
A1  - Linu Jacob
A1  - Loknatha Dasappa
A1  - Suresh Babu Chikkadasappa
A1  - Rudresha Halleshappa
A1  - Rajeev Krishnappa
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2016
VL  - 5
IS  - 5
DO  - 10.4103/2278-0513.197863
SP  - 369
EP  - 373
N2  - Introduction: Mantle cell lymphoma has an aggressive course, with unfavorable outcomes. Subjects and Methods: A retrospective analysis was undertaken and 77 cases were identified between 2009 and 2014. Results: Median age was 55 years with a male to female ratio of 6:1. Patients with pure nodal disease at presentation were fewer than with extranodal disease (53.2%). Most common extranodal site was bone marrow. A number of patients with low-, low-intermediate, high-intermediate, and high-risk International Prognostic Index (IPI) scores were 6, 24, 22, and 25. Treatment consisted of cyclophosphamide,hydroxydaunorubicin, oncovin, prednisolone (CHOP) or R-CHOP regimens. Median survival was 21 months. Median overall survival with early and advanced disease was 31 and 18 months (P = 0.02). Patients who received R-CHOP survived better than those given CHOP, 30 and 16 months (P = 0.0002). There was no difference in survival with respect to age, gender, extranodal, or bone marrow involvement. Conclusions: Most patients presented with extranodal disease, advanced stage, and high IPI. Although rituximab has improved survival, intensive chemotherapy would be required to improve survival.
UR  - https://ccij-online.org/article/clinical-profile,-treatment,-and-outcomes-of-patients-with-mantle-cell-lymphoma-treated-in-a-tertiary-care-center-in-south-india-619
ER  -